FDA
-
-
-
-
-
-
-
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
-
-
-
-
-
-
-
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Moderna (MRNA) PT Raised to $45 at Bernstein SocGen Group
-
-
-
-
-
-
-
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
-
-
-
-
-
-
-
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
-
-
-
-
-
-
-
Global AI Infrastructure Shift Ignites Biotech Growth Phase
-
-
-
-
-
-
-
Brookline: 'We currently estimate that 2025 Moderna COVID-19 vaccine sales will include 10.9 million doses in the US'
-
327,034 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

